Ceribell

Sunnyvale, CA, United States All United States companies → — Founded 2014

Medical Device / Hardware Point-of-Care Diagnostics Specialty-Focused AI

Critical Care Emergency Medicine Neurology

Neurology AI Triage & ER/ICU AI

Public (formerly VC-backed)

Claim this company

Products

Ceribell Status Epilepticus Monitor

Ceribell

Neurology AI

Ceribell offers a novel, point-of-care EEG system with AI-powered algorithms for rapid diagnosis and continuous monitoring of serious neurological conditions like status epilepticus, delirium, and suspected LVO stroke in acute care settings.

Ceribell Delirium Monitor System

Ceribell

Neurology AI

The Ceribell Delirium Monitor System is an AI-powered, point-of-care EEG platform for rapid diagnosis and continuous monitoring of delirium and seizures in acute care settings.

Contact for pricing

See all 2 products →

About Ceribell

Ceribell is a medical technology company that has developed a novel, point-of-care electroencephalography (EEG) platform, the Ceribell System, designed to transform the diagnosis and management of patients with serious neurological conditions in acute care settings. This system addresses the critical need for rapid and accessible EEG monitoring in environments such as emergency departments and intensive care units, where traditional EEG processes can be slow and resource-intensive.

The Ceribell System integrates proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms. This combination allows for quick diagnosis and continuous monitoring of patients at risk for conditions like non-convulsive seizures and status epilepticus. The system is FDA 510(k) cleared for indicating suspected seizure activity and aims to improve clinical outcomes, reduce time-to-treatment, and potentially lower healthcare costs by making rapid EEG a frontline hospital capability.

Focus Areas

point-of-care EEG rapid seizure detection delirium monitoring AI-powered neurodiagnostics acute neurological conditions critical care monitoring

Business Intelligence

Technology

Cloud-linked, portable electroencephalogram (EEG) device with AI-powered algorithms (Clarity, ClarityPro) for real-time monitoring and analysis, cloud-hosted portal for secure review and continuous AI monitoring.

What Physicians Need to Know

Point-of-Care EEG & Rapid Deployment

Ceribell offers a portable, rapid-response EEG system designed for use in emergency departments (EDs) and intensive care units (ICUs). It features a flexible headband with 10 electrodes and a battery-powered recorder that can be applied by any trained healthcare provider in under five minutes, eliminating the need for specialized EEG technologists.

AI-Powered Seizure Detection & Delirium Monitoring

The system incorporates Ceribell's proprietary AI algorithm, Clarity, which continuously monitors EEG signals in real-time. Clarity detects seizure activity and quantifies seizure burden over 5-minute intervals, providing bedside alerts for suspected nonconvulsive seizures and status epilepticus. Ceribell also offers an FDA-cleared Delirium Monitor System, utilizing a machine learning model to analyze EEG signals for features indicative of delirium, integrating both seizure and delirium monitoring into a single platform.

Improved Clinical Workflow & Outcomes

Ceribell's system aims to reduce delays in diagnosing and treating acute neurological conditions, leading to faster diagnosis, more targeted treatment, and potentially improved patient outcomes. Studies have shown shorter ICU lengths of stay and better neurological outcomes with Ceribell compared to conventional EEG. The disposable headband eliminates cleaning steps, simplifying workflow and reducing infection risk.

Evidence-Backed & Regulatory Recognition

Ceribell's technology is backed by peer-reviewed studies and has received FDA clearance for detecting nonconvulsive seizures and electrographic status epilepticus, as well as for aiding in delirium screening and monitoring. The Clarity algorithm has also received a New Technology Add-on Payment (NTAP) from CMS, providing additional reimbursement for eligible Medicare patients.

Secure & Intuitive Portal

The Ceribell EEG Portal allows for remote, real-time review of EEG data with pre-annotated insights. It offers an enhanced mobile experience and features like custom notifications, smart EEG reports with reimbursement-ready language, and an advanced algorithm with an Insights Bar to minimize false alerts.

Physician Tip

For physicians, Ceribell offers a critical tool for rapid neurological assessment in acute care settings. The ease of use and quick application by any trained staff member means faster access to vital EEG data, which is crucial for conditions like nonconvulsive seizures where 'time is brain'. The AI-powered Clarity algorithm provides real-time alerts and seizure burden quantification, aiding in immediate treatment decisions and potentially improving patient outcomes by reducing diagnostic and treatment delays. The integrated delirium monitoring further enhances comprehensive neurological assessment at the bedside. The remote viewing portal allows neurologists to review EEGs efficiently from anywhere, prioritizing cases and streamlining reporting with automated summaries. While the device provides valuable diagnostic information, it's important to remember that it is a diagnostic tool and does not substitute for EEG review by a qualified clinician.

Ceribell offers EMR integration to connect EEG data directly to a hospital's electronic health record system. This integration aims to reduce duplicate data entry, speed up billing processes, and provide bedside teams with more time for patient care, while also allowing remote access to records for neurologists with reduced administrative burden.

Products by Ceribell

2 products in the directory

Ceribell Status Epilepticus Monitor

Ceribell

Neurology AI

Ceribell Delirium Monitor System

Ceribell

Neurology AI

The Ceribell Delirium Monitor System is an AI-powered, point-of-care EEG platform for rapid diagnosis and continuous monitoring of delirium and seizures in acute care settings.

Contact for pricing

What the Web Says

Ceribell is a medical technology company that has developed an AI-powered point-of-care EEG system for rapid seizure detection and management in acute care settings. The product is generally well-received by healthcare providers for its ease of use and ability to expedite diagnoses, potentially reducing ICU stays and improving patient outcomes. However, there are mixed opinions regarding the accuracy of its AI, with some neurologists expressing concerns about false positives and its limitations compared to a full 18-channel EEG. As an employer, Ceribell receives mixed reviews, with some employees praising the product and team, while others highlight issues with company culture, management, and compensation.

Overall: Mixed

Strengths

Game-changing product that is well-received by the market.
Easy to use and apply, allowing for rapid assessment and treatment.
Reduces diagnosis time for seizures and non-seizure conditions.
Can lead to shorter ICU stays and improved neurological outcomes.
Useful in settings without 24/7 in-house EEG technicians.
Highly capable and motivated team.

Limitations

AI aspects are not always impressive and can have high false positive rates.
Does not replace a full montage EEG and has limitations in capturing all brain areas.
Expensive single-use caps contribute to high running costs.
Concerns about company culture, favoritism, and lack of trust among employees.
Compensation may not be fairly evaluated based on job responsibilities, and bonuses can be minimal.
Some employees felt that unnecessary roles were created, leading to frustration.

Based on reviews from: Indeed.com, Comparably, SimplyHired, FeaturedCustomers, TIME, Reddit (r/neurology, r/MedicalDevices), PMC (PubMed Central), Medical Device Network, Capterra, G2

Last updated: 2026-07-17

Videos

News, demos, and interviews about Ceribell.

Loading videos...

Videos load interactively. If none appear, search YouTube for Ceribell →

View all on YouTube

Press & Coverage

BioSpace

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell received FDA 510(k) clearance for new software that enhances the Ceribell System with quantitative EEG trending and amplitude-integrated EEG analysis, making it easier for clinicians to interpret longitudinal brain activity.

2026-09

PR Newswire

Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review

Ceribell announced FDA clearance for new AI-driven algorithms in its Neurology Portal, designed to improve EEG evaluation by filtering complex background interference and streamlining the review of lengthy brain recordings in critical care settings.

2026-08

BioSpace

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

Ceribell received FDA 510(k) clearance for its proprietary delirium monitoring solution, the first and only FDA-cleared device for continuous delirium screening and monitoring, expanding the Ceribell System's capabilities beyond seizure detection.

2025-12

PR Newswire

Ceribell Announces Publication of Study Demonstrating Significant Reduction in Length of ICU Stays and Better Patient Outcomes with Ceribell Point-of-Care EEG Compared to Conventional EEG

A study published by Ceribell demonstrated that the use of its point-of-care EEG system led to a significant reduction in ICU length of stays and improved patient outcomes compared to conventional EEG.

2024-07

MD+DI

Ceribell Looks to Make Its Public Debut Amid Medtech IPO Drought

Ceribell aimed to go public, seeking to raise $101 million in an IPO, highlighting its portable EEG platform with AI for seizure monitoring as a solution to limitations in traditional EEG technology.

2024-10

PR Newswire

Ceribell Receives FDA 510(k) Clearance and CMS NTAP Reimbursement for New ClarityPro™ Software with Electrographic Status Epilepticus Diagnostic Indication

Ceribell's ClarityPro software received FDA 510(k) clearance for diagnosing Electrographic Status Epilepticus (ESE) and was granted New Technology Add-on Payment (NTAP) by CMS, making it the only FDA-indicated device for ESE diagnosis with NTAP reimbursement.

2023-08

Medtech MVP

From Conception to Commercialization, Jane Chao and Ceribell Are Changing Lives With This Neuromonitoring Breakthrough.

An interview with CEO Jane Chao details Ceribell's journey from concept to a commercial, FDA-cleared product, emphasizing the ClarityPro's role in rapid detection and response to non-convulsive seizures in critical care.

2023-09

PR Newswire

Ceribell Closes $50 Million Equity Financing Round Led by Ally Bridge Group

Ceribell closed a $50 million financing round, an extension of its Series C, led by Ally Bridge Group, to support commercial expansion and further development of its machine learning capabilities for other neurological conditions.

2022-09

Frequently Asked Questions

What neurological conditions can the Ceribell system monitor and diagnose?

The Ceribell system is FDA-cleared for the rapid detection and continuous monitoring of suspected seizure activity, including electrographic status epilepticus (ESE), in adults, pediatric patients, and pre-term neonates. Additionally, it is the first and only FDA-cleared solution for continuous delirium monitoring and has received FDA Breakthrough Device Designation for in-hospital Large Vessel Occlusion (LVO) stroke detection.

How does Ceribell's AI-powered point-of-care EEG system work, and what are its key advantages for acute care settings?

The Ceribell system utilizes a disposable headband (or headcap for neonates) and a pocket-sized recorder, enabling rapid EEG setup by trained healthcare providers in minutes at the patient's bedside. Its proprietary Clarity AI algorithm continuously monitors brain activity, providing real-time alerts for conditions like seizures and delirium, and streaming data to a HIPAA-compliant web portal for remote neurologist review. This facilitates faster diagnosis, more informed treatment decisions, and can potentially reduce ICU length of stay.

What regulatory clearances and designations has Ceribell received for its products?

Ceribell holds multiple FDA 510(k) clearances for its point-of-care EEG system, including for seizure detection across all age groups (pre-term neonates through adults), and for its delirium monitoring solution. The company has also been granted FDA Breakthrough Device Designation for its LVO stroke detection monitor, highlighting its potential to address unmet medical needs.

What is the cost-effectiveness of the Ceribell system, and how is reimbursement handled?

While specific pricing is not publicly disclosed, studies suggest that using Ceribell may lead to significant cost savings by reducing hospital and ICU lengths of stay and preventing unnecessary treatment escalations. Ceribell's ClarityPro software for ESE diagnosis has received New Technology Add-on Payment (NTAP) coverage from CMS, and an NTAP application has also been submitted for its delirium monitoring indication to support reimbursement.

What level of training and support does Ceribell provide for healthcare professionals using their system?

Ceribell's system is designed for ease of use, allowing non-neurologist healthcare professionals, such as nurses and emergency physicians, to apply and initiate monitoring after a short training session. The company provides technical support and general inquiry contact lines, and offers remote access to real-time EEG data through a web portal for neurologists to review and guide treatment decisions.

How reliable and accurate are Ceribell's AI-powered algorithms for detecting neurological events?

Ceribell's Clarity AI algorithm is trained on extensive datasets of expert-annotated critical care EEGs and is designed to detect and rule out life-threatening continuous seizures, including status epilepticus, with high sensitivity and specificity. For example, Clarity has demonstrated 95% sensitivity and 97% specificity for alerting to suspected status epilepticus in adults, and 94% sensitivity and 95% specificity for detecting u226590% seizure burden in neonates.

What is Ceribell's company stability and market presence in the healthcare industry?

Ceribell is a medical technology company headquartered in Sunnyvale, California, and is publicly traded on Nasdaq (CBLL). The company has raised substantial funding, with a total of $188M over four rounds, and reported strong revenue growth in 2025. Its system is currently utilized in over 600 hospitals across the U.S., having assessed more than 200,000 patients.